Funding

Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed life sciences fund, bringing its total raised since 2021 to $430 million. The company says it has completed more than 100 patient procedures at 18 medical institutions and holds FDA clearance for its Layer 7 Cortical Interface, a thin-film electrode array placed on the brain surface. It plans to use the money to expand clinical work, move Layer 7 through the next stages of FDA review and build out commercialization.

China's brain-computer interface sector recorded 47 funding rounds in the first half of 2026, 38 of them disclosing terms for a combined RMB 5.38 billion (approx. $750 million). A broader tally used by Chinese financial media puts the total at 64 deals and roughly RMB 7.25 billion (approx. $1 billion). Either figure is more than double the whole of 2025 (49 deals, RMB 2.72 billion) at a comparable deal count. The record lists every deal by month — company, technical approach, round, amount, investors — and identifies three structural patterns: ultrasound and non-invasive approaches moving quickly into a field long defined by implants, Big Tech and municipal state funds entering at the same time, and nearly half of all transactions still sitting at angel or seed stage.

People's Daily Online reported that BrainCo completed an RMB 2 billion Series B+ round in January 2026, the largest single BCI financing in China at the time. The report did not disclose the lead investor, a complete investor list or the post-money valuation. The round indicates a capital-intensive expansion phase across BrainCo's non-invasive and medical product lines.

Synchron raised a $200 million Series D led by Double Point Ventures, taking its total funding to $345 million. The company plans to use the capital to commercialize its Stentrode endovascular BCI, prepare pivotal trials and expand its AI and engineering teams. Synchron said 10 people with paralysis had received the implant in U.S. and Australian trials at the time of the announcement.